3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Conditions
Precancerous Conditions
162
Leukemia
43
Lymphoma
42
Multiple Myeloma
39
Leukemia, Lymphocytic, Chronic, B-Cell
39
Neoplasms, Plasma Cell
37
Precursor Cell Lymphoblastic Leukemia-Lymphoma
36
Lymphoma, Non-Hodgkin
35
Lymphoma, Mantle-Cell
35
Lymphoma, Large-Cell, Immunoblastic
35
Lymphoma, Large B-Cell, Diffuse
35
Lymphoma, Follicular
35
Monoclonal Gammopathy of Undetermined Significance
34
Burkitt Lymphoma
34
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
33
Lymphoma, B-Cell, Marginal Zone
33
Myeloproliferative Disorders
32
Myelodysplastic Syndromes
32
Leukemia, Myeloid, Acute
32
Hodgkin Disease
32
Immunoblastic Lymphadenopathy
31
Lymphoma, Large-Cell, Anaplastic
30
Immunoglobulin Light-chain Amyloidosis
30
Waldenstrom Macroglobulinemia
29
Primary Myelofibrosis
29
Thrombocythemia, Essential
28
Leukemia, Hairy Cell
28
Leukemia, Biphenotypic, Acute
28
Lymphoma, T-Cell, Cutaneous
27
Leukemia, Prolymphocytic
27
Interventions
Psychotherapy
1
Psilocybin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Hospice
×
Other neoplasm
×
Clear all
NCT04950608
2026-02-17
PATH
Dana-Farber Cancer Institute
Phase 2
Completed
15 enrolled
26 charts